Medical marijuana upstart Insys Therapeutics (NASDAQ: INSY) had a ferociously frightening month, highlighted by the arrest of its founder, the setting aside of $150 million for lawsuits, and slumping sales. All this was behind a 42% crash in October, according to S&P Global Market Intelligence.
Insys Therapeutics’ troubles stem from Subsys, a powerful fentanyl spray approved to treat breakthrough pain in cancer patients.
IMAGE SOURCE: GETTY IMAGES.